Kazia Therapeutics Limited (NasdaqCM: KZIA)
Health Care · Biotechnology · AU
$13.41
-0.85% today · +73.9% 1Y
Kazia Therapeutics Limited (NasdaqCM: KZIA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $153.18M and employs 6 people.
Over the last twelve months the share price has gained 73.9%, trading between 4.86 and 17.40.
Tweenvest scores Kazia Therapeutics Limited across four factors: quality 28/100, value 43/100. Its strongest factor is value.
KZIA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $153.18M
- Revenue (TTM)
- $1.27M
- P/E
- —
- EPS
- -10.22
- Dividend yield
- —
- Beta (5Y)
- 2.14
- 52-week high
- $17.40
- 52-week low
- $4.86
- Avg volume (3M)
- —
- Shares outstanding
- 11.43M
- Employees
- 6
- Next earnings
- —
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- ISIN
- US48669G3039
- Founded
- 1994
- Listed since
- Jan 6, 1999
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.